Guillaume Lamotte
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Guillaume Lamotte has a total of 171 co-authors. Here are the top co-authors by number of shared publications:
Elizabeth A. Coon
Department of Neurology, Mayo Clinic, Rochester, MN (G.L., E.A.C., M.D.S., P.S., E.B., J.K.C.-G., M.L.M., S.E.B., K.S., D.S., P.A.L., W.S.).
5 shared publications- Daniel M. Corcos
Department of Physical Therapy & Human Movement Sciences Northwestern University Chicago IL USA
4 shared publications David S. Goldstein
Clinical Neurosciences Program/Division of Intramural Research (DIR)/National Institute of Neurological Disorders and Stroke (NINDS)/National Institutes of Health (NIH)
4 shared publicationsEduardo E. Benarroch
Mayo Clinic, Department of Neurology, Rochester, MN, USA
4 shared publications- Kathleen E. McKee
Intermountain Health, Neurosciences Clinical Program, Salt Lake City, UT, USA
4 shared publications Paola Sandroni
Department of Neurology, Mayo Clinic, Rochester, USA
4 shared publications
Latest Publications
- Open Access
- 6 October 2026
- Published by Frontiers Media SA in Frontiers in Neuroscience
- Vol. 20, 1929006
Hemodynamics, plasma catecholamines, and power spectral analysis of heart rate variability during tilt-evoked neurally mediated hypotension
Background: Syncope workup often includes tilt table testing. One positive result is neurally mediated hypotension (NMH). Mechanisms of NMH are debated. Objectives: We characterized NMH development in terms of systemic and forearm hemodynamics, plasma catecholamines, and power spectral analysis of heart rate variability. Methods: We reviewed data from 25 subjects with NMH and 34 controls without NMH who had autonomic testing between 2003 and 2024. Dependent measures included continuously recorded blood pressure (BP), heart rate, stroke volume, cardiac output, respiratory rate (RR), forearm blood flow (FBF), forearm vascular resistance (FVR), systemic vascular resistance (SVR), plasma epinephrine and norepinephrine, and high- and low-frequency power of heart rate variability (HF RR and LF RR ). There were 4 study periods: T0 = supine rest; T1 = start of tilt; T2 = NMH (20 min of tilting in controls); and T3 = supine recovery. Results: There were significant interaction effects for Group X Study Period for several variables, with a decrease in BP, FVR, SVR, HF RR , and LF RR , and an increase in FBF and epinephrine at a steeper rate in the NMH group compared to the No NMH group. The two groups did not differ in responses of heart rate, RR, stroke volume, cardiac output, or norepinephrine levels. The increment in plasma epinephrine was larger in the NMH group, without a group difference in norepinephrine (i.e., sympathoadrenal imbalance). LF RR was elevated at baseline and decreased markedly in participants developing NMH. Conclusions: NMH is associated with forearm vasodilation, sympathoadrenal imbalance, and a precipitous fall in LF RR . The results fit with a neurocirculatory-neuroendocrine pattern triggering NMH.
- 6 October 2026
- Published by Frontiers Media SA in Frontiers in Neuroscience
- Vol. 20, 1929006
Open AccessHemodynamics, plasma catecholamines, and power spectral analysis of heart rate variability during tilt-evoked neurally mediated hypotension
Background: Syncope workup often includes tilt table testing. One positive result is neurally mediated hypotension (NMH). Mechanisms of NMH are debated. Objectives: We characterized NMH development in terms of systemic and forearm hemodynamics, plasma catecholamines, and power spectral analysis of heart rate variability. Methods: We reviewed data from 25 subjects with NMH and 34 controls without NMH who had autonomic testing between 2003 and 2024. Dependent measures included continuously recorded blood pressure (BP), heart rate, stroke volume, cardiac output, respiratory rate (RR), forearm blood flow (FBF), forearm vascular resistance (FVR), systemic vascular resistance (SVR), plasma epinephrine and norepinephrine, and high- and low-frequency power of heart rate variability (HF RR and LF RR ). There were 4 study periods: T0 = supine rest; T1 = start of tilt; T2 = NMH (20 min of tilting in controls); and T3 = supine recovery. Results: There were significant interaction effects for Group X Study Period for several variables, with a decrease in BP, FVR, SVR, HF RR , and LF RR , and an increase in FBF and epinephrine at a steeper rate in the NMH group compared to the No NMH group. The two groups did not differ in responses of heart rate, RR, stroke volume, cardiac output, or norepinephrine levels. The increment in plasma epinephrine was larger in the NMH group, without a group difference in norepinephrine (i.e., sympathoadrenal imbalance). LF RR was elevated at baseline and decreased markedly in participants developing NMH. Conclusions: NMH is associated with forearm vasodilation, sympathoadrenal imbalance, and a precipitous fall in LF RR . The results fit with a neurocirculatory-neuroendocrine pattern triggering NMH.
- Open Access
- 17 December 2025
- Published by Ubiquity Press, Ltd. in Tremor and Other Hyperkinetic Movements
- Vol. 15 (1)
A Case Report of Abdominal Myoclonus Following Anterior Cerebral Artery Stroke
Post-stroke movement disorders are rare. Abdominal myoclonus following anterior cerebral artery (ACA) infarction has not been previously reported. A 75-year-old man presented with acute right-sided weakness and involuntary, rhythmic contractions of the abdominal muscles. Imaging revealed an acute left ACA infarction involving the precentral gyrus. Scalp electroencephalography (EEG) showed no epileptiform discharges. Other secondary causes of myoclonus were ruled out. Abdominal myoclonus resolved after intravenous levetiracetam. This case highlights cortical abdominal myoclonus as a rare manifestation of ACA ischemic stroke. Epileptiform abnormalities on EEG are often not found. Treatment with an antiepileptic medication may resolve the myoclonus.
- 17 December 2025
- Published by Ubiquity Press, Ltd. in Tremor and Other Hyperkinetic Movements
- Vol. 15 (1)
Open AccessA Case Report of Abdominal Myoclonus Following Anterior Cerebral Artery Stroke
Post-stroke movement disorders are rare. Abdominal myoclonus following anterior cerebral artery (ACA) infarction has not been previously reported. A 75-year-old man presented with acute right-sided weakness and involuntary, rhythmic contractions of the abdominal muscles. Imaging revealed an acute left ACA infarction involving the precentral gyrus. Scalp electroencephalography (EEG) showed no epileptiform discharges. Other secondary causes of myoclonus were ruled out. Abdominal myoclonus resolved after intravenous levetiracetam. This case highlights cortical abdominal myoclonus as a rare manifestation of ACA ischemic stroke. Epileptiform abnormalities on EEG are often not found. Treatment with an antiepileptic medication may resolve the myoclonus.
- Open Access
- 26 September 2025
- Published by SAGE Publications in Journal of Parkinson’s Disease
- Vol. 15 (8) , 1345-1352
Advice to people with Parkinson's in my clinic: How to manage running-induced dystonia
Exercise is an essential part of the treatment of Parkinson's disease. However, certain symptoms can make exercise difficult. In this viewpoint, we describe an under recognized symptom called running-induced dystonia (RID), which can prevent people with Parkinson's from exercising in their preferred way. We summarize the existing literature and use three case studies to outline potential mechanisms, aggravating and relieving factors and both pharmacological and non-pharmacological therapies to get rid of RID.
- 26 September 2025
- Published by SAGE Publications in Journal of Parkinson’s Disease
- Vol. 15 (8) , 1345-1352
Open AccessAdvice to people with Parkinson's in my clinic: How to manage running-induced dystonia
Exercise is an essential part of the treatment of Parkinson's disease. However, certain symptoms can make exercise difficult. In this viewpoint, we describe an under recognized symptom called running-induced dystonia (RID), which can prevent people with Parkinson's from exercising in their preferred way. We summarize the existing literature and use three case studies to outline potential mechanisms, aggravating and relieving factors and both pharmacological and non-pharmacological therapies to get rid of RID.
- 8 September 2025
- Published by Springer Nature in Clinical Autonomic Research
- Vol. 35 (6) , 861-862
Orthostatic hypotension in Parkinson’s disease—More than just lightheadedness and fainting
- 8 September 2025
- Published by Springer Nature in Clinical Autonomic Research
- Vol. 35 (6) , 861-862
Orthostatic hypotension in Parkinson’s disease—More than just lightheadedness and fainting
- 21 April 2025
- Published by Springer Nature in Clinical Autonomic Research
- Vol. 35 (4) , 623-627
“Body-first” dementia with Lewy bodies
- 21 April 2025
- Published by Springer Nature in Clinical Autonomic Research
- Vol. 35 (4) , 623-627
“Body-first” dementia with Lewy bodies
- Open Access
- 13 April 2025
- Published by SAGE Publications in Journal of Parkinson’s Disease
- Vol. 15 (3) , 654-663
Advice to people with Parkinson's in my clinic: Get a cardiopulmonary exercise test
Aerobic (cardiopulmonary) exercise training improves fitness and limits the progression of motor signs in Parkinson's disease. Individualized development of exercise prescriptions relies upon accurately measured peak heart rate (HR). Cardiopulmonary exercise testing (CPET) is the only methodology to objectively confirm an individual's peak HR. This test is important in individuals who may have autonomic dysfunction, which may manifest as chronotropic incompetence. Without CPET's confirmation of maximal effort, there is no way of knowing whether exercise prescription in those with chronotropic incompetence is accurate. CPET also provides information regarding cardiorespiratory fitness, which can motivate patients to exercise to prolong health.
- 13 April 2025
- Published by SAGE Publications in Journal of Parkinson’s Disease
- Vol. 15 (3) , 654-663
Open AccessAdvice to people with Parkinson's in my clinic: Get a cardiopulmonary exercise test
Aerobic (cardiopulmonary) exercise training improves fitness and limits the progression of motor signs in Parkinson's disease. Individualized development of exercise prescriptions relies upon accurately measured peak heart rate (HR). Cardiopulmonary exercise testing (CPET) is the only methodology to objectively confirm an individual's peak HR. This test is important in individuals who may have autonomic dysfunction, which may manifest as chronotropic incompetence. Without CPET's confirmation of maximal effort, there is no way of knowing whether exercise prescription in those with chronotropic incompetence is accurate. CPET also provides information regarding cardiorespiratory fitness, which can motivate patients to exercise to prolong health.
- Open Access
- 14 January 2025
- Published by SAGE Publications in Journal of Parkinson’s Disease
- Vol. 15 (2) , 387-396
Effects of 6 months of endurance exercise on motor function, exercise capacity, and autonomic function based on presence of autonomic dysfunction in individuals with early Parkinson's disease
Background: Endurance exercise improves aerobic capacity (VO 2peak ) and motor symptoms in people with early Parkinson's disease (PD). Some people with PD exhibit signs of chronotropic incompetence (CI), which may impact exercise-induced benefits. Objective: We investigated whether CI in people with early PD influences the change in motor signs, VO 2peak , and peak heart rate (HR) following 6 months of endurance exercise. Methods: We performed secondary analyses of the Study in Parkinson's Disease of Exercise (SPARX), which randomized people with early PD into a high-intensity endurance exercise [80–85% of peak HR], moderate-intensity endurance exercise [60–65% of peak HR], or usual care group. MDS-UDPRS Part 3 score, VO 2peak , and heart rate (HR) response to maximal cardiopulmonary exercise testing (CPET) were analyzed at baseline and following 6 months of exercise. Participants were divided into three groups: 1) normal chronotropic response at baseline, 2) CI at baseline, and 3) taking medications with a known negative chronotropic effect regardless of CI status. Results: Data from 119 individuals (64.0 ± 9.0 years, 57.1% male, 0.3 years since diagnosis [median]) were analyzed. There were no differences among the groups in change in MDS-UPDRS motor score ( p = 0.953), VO 2peak ( p = 0.965), or peak HR ( p = 0.388). People randomized into the high-intensity group improved VO 2peak compared to usual care ( p < 0.001 adj ) regardless of CI status. Conclusions: Baseline CI did not alter responses to endurance exercise in those with early PD, suggesting that the beneficial effects of endurance exercise on disease progression and VO 2peak in people with early PD apply equally to people with CI.
- 14 January 2025
- Published by SAGE Publications in Journal of Parkinson’s Disease
- Vol. 15 (2) , 387-396
Open AccessEffects of 6 months of endurance exercise on motor function, exercise capacity, and autonomic function based on presence of autonomic dysfunction in individuals with early Parkinson's disease
Background: Endurance exercise improves aerobic capacity (VO 2peak ) and motor symptoms in people with early Parkinson's disease (PD). Some people with PD exhibit signs of chronotropic incompetence (CI), which may impact exercise-induced benefits. Objective: We investigated whether CI in people with early PD influences the change in motor signs, VO 2peak , and peak heart rate (HR) following 6 months of endurance exercise. Methods: We performed secondary analyses of the Study in Parkinson's Disease of Exercise (SPARX), which randomized people with early PD into a high-intensity endurance exercise [80–85% of peak HR], moderate-intensity endurance exercise [60–65% of peak HR], or usual care group. MDS-UDPRS Part 3 score, VO 2peak , and heart rate (HR) response to maximal cardiopulmonary exercise testing (CPET) were analyzed at baseline and following 6 months of exercise. Participants were divided into three groups: 1) normal chronotropic response at baseline, 2) CI at baseline, and 3) taking medications with a known negative chronotropic effect regardless of CI status. Results: Data from 119 individuals (64.0 ± 9.0 years, 57.1% male, 0.3 years since diagnosis [median]) were analyzed. There were no differences among the groups in change in MDS-UPDRS motor score ( p = 0.953), VO 2peak ( p = 0.965), or peak HR ( p = 0.388). People randomized into the high-intensity group improved VO 2peak compared to usual care ( p < 0.001 adj ) regardless of CI status. Conclusions: Baseline CI did not alter responses to endurance exercise in those with early PD, suggesting that the beneficial effects of endurance exercise on disease progression and VO 2peak in people with early PD apply equally to people with CI.
- Open Access
- 1 December 2024
- Published by Wolters Kluwer Health in Neurology Clinical Practice
- Vol. 14 (6) , e200345
A General Neurologist's Practical Diagnostic Algorithm for Atypical Parkinsonian Disorders
The most common four neurodegenerative atypical parkinsonian disorders (APDs) are progressive supranuclear palsy (PSP), multiple system atrophy (MSA), corticobasal syndrome (CBS), and dementia with Lewy bodies (DLB). Their formal diagnostic criteria often require subspecialty experience to implement as designed and all require excluding competing diagnoses without clearly specifying how to do that. Validated diagnostic criteria are not available at all for many of the other common APDs, including normal pressure hydrocephalus (NPH), vascular parkinsonism (VP), or drug-induced parkinsonism (DIP). APDs also include conditions of structural, genetic, vascular, toxic/metabolic, infectious, and autoimmune origin. Their differential diagnosis can be challenging early in the course, if the presentation is atypical, or if a rare or non-neurodegenerative condition is present. This review equips community general neurologists to make an early provisional diagnosis before, or in place of, referral to a tertiary center. Early diagnosis would allay diagnostic uncertainty, allow prompt symptomatic management, provide disease-specific information and support resources, avoid further pointless testing and treatments, and create the possibility of trial referral. We address 64 APDs using one over-arching flow diagram and a series of detailed tables. Most instances of APDs can be diagnosed with a careful history and neurological exam, along with a non-contrast brain MRI. Additional diagnostic tests are rarely needed but are delineated where applicable. Our diagnostic algorithm encourages referral to a tertiary center whenever the general neurologist feels it would be in the patient's best interest. Our algorithm emphasizes that the diagnosis of APDs is an iterative process, refined with the appearance of new diagnostic features, availability of new technology, and advances in scientific understanding of the disorders. Clinicians' proposals for all diagnostic tests for the APDs, including repeat visits, should be discussed with patients and their families to ensure that the potential information to be gained aligns with their larger clinical goals. We designed this differential diagnostic algorithm for the APDs to enhance general neurologists' diagnostic skills and confidence and to help them address the less common or more ambiguous cases.
- 1 December 2024
- Published by Wolters Kluwer Health in Neurology Clinical Practice
- Vol. 14 (6) , e200345
Open AccessA General Neurologist's Practical Diagnostic Algorithm for Atypical Parkinsonian Disorders
The most common four neurodegenerative atypical parkinsonian disorders (APDs) are progressive supranuclear palsy (PSP), multiple system atrophy (MSA), corticobasal syndrome (CBS), and dementia with Lewy bodies (DLB). Their formal diagnostic criteria often require subspecialty experience to implement as designed and all require excluding competing diagnoses without clearly specifying how to do that. Validated diagnostic criteria are not available at all for many of the other common APDs, including normal pressure hydrocephalus (NPH), vascular parkinsonism (VP), or drug-induced parkinsonism (DIP). APDs also include conditions of structural, genetic, vascular, toxic/metabolic, infectious, and autoimmune origin. Their differential diagnosis can be challenging early in the course, if the presentation is atypical, or if a rare or non-neurodegenerative condition is present. This review equips community general neurologists to make an early provisional diagnosis before, or in place of, referral to a tertiary center. Early diagnosis would allay diagnostic uncertainty, allow prompt symptomatic management, provide disease-specific information and support resources, avoid further pointless testing and treatments, and create the possibility of trial referral. We address 64 APDs using one over-arching flow diagram and a series of detailed tables. Most instances of APDs can be diagnosed with a careful history and neurological exam, along with a non-contrast brain MRI. Additional diagnostic tests are rarely needed but are delineated where applicable. Our diagnostic algorithm encourages referral to a tertiary center whenever the general neurologist feels it would be in the patient's best interest. Our algorithm emphasizes that the diagnosis of APDs is an iterative process, refined with the appearance of new diagnostic features, availability of new technology, and advances in scientific understanding of the disorders. Clinicians' proposals for all diagnostic tests for the APDs, including repeat visits, should be discussed with patients and their families to ensure that the potential information to be gained aligns with their larger clinical goals. We designed this differential diagnostic algorithm for the APDs to enhance general neurologists' diagnostic skills and confidence and to help them address the less common or more ambiguous cases.
- Open Access
- 1 August 2024
- Published by SAGE Publications in Journal of Parkinson’s Disease
- Vol. 14 (6) , 1139-1146
Advice to People with Parkinson’s in My Clinic: Orthostatic Hypotension
Orthostatic hypotension (OH) is the most common manifestation of cardiovascular autonomic dysfunction in Parkinson’s disease. In this viewpoint, we discuss five practical questions regarding OH in Parkinson’s disease: 1) How common is the problem? 2) Why should people with Parkinson’s disease and providers care about OH? 3) What are the symptoms of OH? 4) How to confirm a diagnosis of OH? And 5) How to treat OH? OH is an important non-motor symptom of Parkinson’s disease for which we have available treatments to significantly mitigate morbidity and possibly positively impact the disease course.
- 1 August 2024
- Published by SAGE Publications in Journal of Parkinson’s Disease
- Vol. 14 (6) , 1139-1146
Open AccessAdvice to People with Parkinson’s in My Clinic: Orthostatic Hypotension
Orthostatic hypotension (OH) is the most common manifestation of cardiovascular autonomic dysfunction in Parkinson’s disease. In this viewpoint, we discuss five practical questions regarding OH in Parkinson’s disease: 1) How common is the problem? 2) Why should people with Parkinson’s disease and providers care about OH? 3) What are the symptoms of OH? 4) How to confirm a diagnosis of OH? And 5) How to treat OH? OH is an important non-motor symptom of Parkinson’s disease for which we have available treatments to significantly mitigate morbidity and possibly positively impact the disease course.